BULLISH ON AZN
AstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases.
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not yet in overbought territory, suggesting there’s still room for growth
Trendline support: The stock is currently around the trendline support
STOCK ANALYSIS
Support Levels: AZN’s stock is trading close to its key support levels, around $66.26, and has shown resilience above the $60 mark, which historically has been a strong support zone. The stock is likely to maintain upward pressure if it holds above this level
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not yet in overbought territory, suggesting there’s still room for growth
Trendline support: The stock is currently around the trendline support
STOCK ANALYSIS
Support Levels: AZN’s stock is trading close to its key support levels, around $66.26, and has shown resilience above the $60 mark, which historically has been a strong support zone. The stock is likely to maintain upward pressure if it holds above this level
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。